p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

By Sanjay Kumar, J. Boehm, John C. Lee. Nature reviews. Drug discovery, 2003

1,263 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/5a3bdb850a5dfb179483a45362a9045befaf5f56

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. M. Suter
2. A. Nebreda
3. Dong Wang
4. S. Hagan
5. R. Ji
6. Walter Kolch
7. Emily Y. Chew
8. Oliver Rath

In Oncology

1. Walter Kolch
2. E. Wagner
3. A. Nebreda
4. T. Mogensen
5. Bozena Kaminska
6. Shaloam Dasari
7. P. Tchounwou

Citations in the corpus

• The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. (2005, background): “The c-Jun amino terminal kinas (JNK) and p38 MAPK pathways may be activated by exposures associated with retinal disease; these include hypoxia, ultraviolet light, inflammatory cytokines, osmotic shock, or environmental stress (Kumar et al., 2003).”
• Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “, 2010b), and p38 MAPK inhibitors are currently being development for the treatment of autoimmune and inflammatory disorders (Kumar et al., 2003) and may have potential in treating cytokine-induced depression.”
• MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits. (2005, background): “Moreover, many of these drugs are small molecules that can be administered orally and a growing number of studies demonstrate their therapeutic benefits in animal models of chronic inflammatory disease [109].”
• The role of oxidative stress in diabetic complications (2007, background): “This subfamily regulates inflammation, differentiation, and proliferation, among other processes (351,352).”
• Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation (2005, background): “A potential mechanism whereby minocycline exerts its anti-inflammatory actions is inhibition of p38 mitogen-activated protein kinase (MAPK), a key regulator of the expression of proinflammatory cytokines and other mediators such as COX-2 (Kumar et al., 2003).”
• MAP kinase signalling pathways in cancer (2007, background): “The four vertebrate isoforms of p38, a, b and g (ERK6) and d are characterized by the presence of the conserved Thr-Gly-Tyr (TGY) phosphorylation motif in their activation loop (Kumar et al., 2003).”
• Signal integration by JNK and p38 MAPK pathways in cancer development (2009, background): “In addition, p38α has a key role in the production of many cytokines, such as TNFα, IL-1 and IL-6, which have pro-inflammatory, pro-survival and angiogenic effect”
• Cellular processing of platinum anticancer drugs (2005, background): “A growing body of evidence indicates that activation of the p38 MAPK pathway has an important role in the cellular response to cisplati”
• p38 MAPK, microglial signaling, and neuropathic pain (2007, background): “p38 inhibitor was shown to effectively alleviate rheumatoid arthritis and inflammatory pain [31-33].”
• Visfatin, an Adipocytokine with Proinflammatory and Immunomodulating Properties1 (2007, background): “Various extracellular signals are integrated and processed by MAPK cascades (44).”
• MAP kinase and pain (2008, background): “The biosynthesis of TNF-α and IL-1β, as well as many other inflammatory mediators is up-regulated by p38 (Kumar et al., 2003).”
• Pathogen Recognition and Inflammatory Signaling in Innate Immune Defenses (2009, background): “tently inhibit p38 / in an ATP-competitive manner, and specific and selective p38 / inhibitors have been demonstrated to block the production of IL-1, TNF- , and IL-6 both in vitro and in vivo, with potential implications for the treatment of inflammatory diseases (197).”